News

The approval is based on data from three clinical studies including Phase Ib KEYNOTE-001 trial, Phase II KEYNOTE-002 trial and Phase III KEYNOTE-006 trial conducted in more than

With this expansion, Pfizer has leased the complete 500,000ft² at 610 Main Street in Kendall Square and this space will continue to house the research and development (R&D)

With the in cell factory technology, living cells can be controlled and manipulated to make specific proteins with therapeutic benefits. Under the deal, MedImmune will provide funding and

The Yokebe is expected to generate about €30m in full year 2015 net sales. Yokebe comes in a shake/liquid form and is marketed within the ‘meal replacement’ category.

The company’s latest report* states that Stelara, an IL12/IL23 inhibitor, has demonstrated a strong safety profile in other indications, and is expected to launch in the US and

Ofatumumab is designed to target the CD20 molecule found on the surface of CLL cells and normal B lymphocytes. The sBLA, which was submitted by Novartis under Genmab’s

Lysogene and Alcyone Lifesciences will join forces to evaluate the intraparenchymal delivery of Lysogene’s proprietary rAAV to treat patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as

Simulations Plus will continue to provide licenses for its GastroPlus, ADMET Predictor, and MedChem Studio software programs for use by the DNTP/NIEHS. The DNTP within the NIEHS is

Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove LDL-C, or "bad" cholesterol, from the blood. Elevated LDL-C is